13 Best Booming Stocks to Buy Right Now

Published on February 21, 2024 at 9:21 am by Fahad Saleem in Hedge Funds, News

In this article, we will take a detailed look at the 13 Best Booming Stocks to Buy Right Now. For a quick overview of such stocks, read our article 5 Best Booming Stocks to Buy Right Now.

Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market turbulence and issuing highly positive outlook for the broader stock market. Goldman Sachs recently increased its S&P 500 target for 2024 to 5200. Goldman said the primary reason for this target revision was strong earnings and profit estimates. Goldman Sachs’ analysts expect strong earnings and growth for IT and communication-services sectors. Some of the best booming stocks of 2023 were from these two sectors, including Microsoft Corp (NASDAQ:MSFT), Apple Inc (NASDAQ:AAPL) and Amazon.com Inc (NASDAQ:AMZN).

Goldman Sachs also said in a note on February 16 that it expects the global manufacturing activity to come back to normal this year. Goldman noted a rate-cut environment is always a positive for risky assets but the market is already pricing in much of the effects of rate cuts that are expected later this year.

Goldman Sachs isn’t the only bullish investment firm in the market. UBS recently increased its 2024 target for the S&P 500 to 5,400. UBS said while latest data shows a hotter-than-expected inflation, it’s also an indicator of a strong consumer demand.

“Higher inflation tends to be a positive for stock prices. While the market sold off on more robust CPI and PPI reports last week, our work indicates that these demand-driven readings are constructive for future returns,” UBS analysts led by Jonathan Golub said.

Photo by Austin Distel on Unsplash

Methodology

Everyone knows stocks like Microsoft Corp (NASDAQ:MSFT), Apple Inc (NASDAQ:AAPL) and Amazon.com Inc (NASDAQ:AMZN) were booming in 2023. But what are the best booming stocks in 2024 so far? For this article we first used a stock screener to find stocks that have gained over 30% year to date through February 19. From these stocks we picked 13 stocks with the highest number of hedge fund investors. We used Insider Monkey’s database of 933 hedge funds updated for the fourth quarter of 2023 to gauge hedge fund sentiment of these stocks. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here).

13. Arm Holdings PLC – ADR (NASDAQ:ARM)

Number of Hedge Fund Investors: 22

Arm Holdings PLC – ADR (NASDAQ:ARM) shares have gained about 86% in 2024 through February 19. The UK-based semiconductor giant went public last year but the shares have been skyrocketing this year amid optimism fueled by AI. The stock recently jumped after Arm Holdings PLC – ADR (NASDAQ:ARM) posted strong Q3 results and gave a strong guidance.

However, Daiwa Securities recently downgraded the stock as the firm believes Arm Holdings PLC – ADR (NASDAQ:ARM) shares have run too much and require a cautious approach.

12. Cullinan Oncology Inc (NASDAQ:CGEM)

Number of Hedge Fund Investors: 22

Cullinan Oncology Inc (NASDAQ:CGEM) shares have gained about 64% year to date. A total of 22 hedge funds in Insider Monkey’s database of 933 funds had stakes in the company as of the end of the fourth quarter of 2023.

11. Viking Therapeutics Inc (NASDAQ:VKTX)

Number of Hedge Fund Investors: 25

Viking Therapeutics Inc (NASDAQ:VKTX) shares have gained about 98% since the start of 2024 through February 19. The stock has gained amid takeover speculation. Earlier this month, Betaville said Eli Lilly (LLY) could be one of the companies interested in buying Viking Therapeutics Inc (NASDAQ:VKTX).

During its Q4 earnings call earlier this month, Viking talked about its catalysts and updated on key business developments:

“The ongoing Phase 1b study of VK0214 is being conducted in patients with the adrenomyeloneuropathy or AMN form of X-ALD, which is the most common form of the disorder. This trial is a randomized, double-blind, placebo-controlled multicenter study in adult male patients with AMN. The primary objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of VK0214 administered orally once daily for 28 days. The study also includes an exploratory assessment of changes in plasma levels of very long chain fatty acids. We expect to report the top line results from this study in the first half of 2024. In conclusion, 2023 was an exciting and productive year for Viking, with the company achieving significant progress with each of our clinical programs.

During the year, we reported the results from the first Phase 1 trial of VK2735, which demonstrated early signals of efficacy as well as promising safety and tolerability. We also initiated the Phase 1 clinical evaluation of a novel oral formulation of VK2735, which we believe may expand the market opportunity for this compound. In the fall of 2023, we initiated and completed the upsized enrolment of the VENTURE Phase 2 trial to evaluate VK2735’s longer-term clinical benefit in patients with obesity. We look forward to reporting the results from the VENTURE Phase 2 study later this quarter, along with the Phase 1 data from the oral formulation study. We also look forward to reporting data from the VOYAGE Phase 2b study of our thyroid beta receptor agonist, VK2809 in biopsy-confirmed NASH and fibrosis.”

Read the entire earnings call transcript here.

10. Applied Therapeutics Inc (NASDAQ:APLT)

Number of Hedge Fund Investors: 25

Applied Therapeutics Inc (NASDAQ:APLT) ranks tenth in our list of the best booming stocks to buy now. The stock has gained about 47% year to date through February 19.

As of the end of the fourth quarter of 2023 25 hedge funds had stakes in Applied Therapeutics Inc (NASDAQ:APLT). The most significant stake in Applied Therapeutics Inc (NASDAQ:APLT) is owned by Fred Knoll’s Knoll Capital Management which owns an $18.3 million stake in Applied Therapeutics Inc (NASDAQ:APLT).

9. Fate Therapeutics Inc (NASDAQ:FATE)

Number of Hedge Fund Investors: 26

Fate Therapeutics Inc (NASDAQ:FATE) shares have gained about 104% year to date through February 19. In November Fate Therapeutics Inc (NASDAQ:FATE) posted third quarter results. GAAP EPS in the period came in at -$0.46, beating estimates by $0.12. Revenue came in at $1.94 million, beating estimates by $1.04 million.

As of the end of the fourth quarter of 2023, 26 hedge funds had stakes in Fate Therapeutics Inc (NASDAQ:FATE). The biggest stakeholder of Fate Therapeutics Inc (NASDAQ:FATE) during this period was Jeremy Green’s Redmile Group which had a $49 million stake in Fate Therapeutics Inc (NASDAQ:FATE).

8. Edgewise Therapeutics Inc (NASDAQ:EWTX)

Number of Hedge Fund Investors: 26

Edgewise Therapeutics Inc (NASDAQ:EWTX) ranks eighth in our list of the best booming stocks to buy right now. The stock jumped in January after Edgewise Therapeutics Inc (NASDAQ:EWTX) priced its offering of 21.8 million shares at $11.00 apiece for gross proceeds of about $240 million.

As of the end of the fourth quarter of 2023, 26 hedge funds tracked by Insider Monkey had stakes in Edgewise Therapeutics Inc (NASDAQ:EWTX).

7. Kinsale Capital Group Inc (NYSE:KNSL)

Number of Hedge Fund Investors: 28

Specialty insurance company Kinsale Capital Group Inc (NYSE:KNSL) shares have gained about 45% year to date through February 19.

As of the end of the fourth quarter of 2023, 28 hedge funds had stakes in Kinsale Capital Group Inc (NYSE:KNSL). The biggest stake in Kinsale Capital Group Inc (NYSE:KNSL) is owned by Bradley Schatz’s Maren Capital which owns a $46 million stake in Kinsale Capital Group Inc (NYSE:KNSL).

Carillon Eagle Small Cap Growth Fund stated the following regarding Kinsale Capital Group, Inc. (NYSE:KNSL) in its fourth quarter 2023 investor letter:

“Kinsale Capital Group, Inc. (NYSE:KNSL) is a specialty insurance company focused on the excess and surplus (E&S) market, serving customers with specialized coverage needs not covered by standard coverage policies. The company reported strong third-quarter results, but its gross written premiums fell short of consensus estimates. The stock retracted after a notably strong run in the previous quarter.”

6. Oscar Health Inc (NYSE:OSCR)

Number of Hedge Fund Investors: 31

Oscar Health Inc (NYSE:OSCR) ranks sixth in our list of the best booming stocks to buy right now. Earlier this month Oscar Health Inc (NYSE:OSCR) posted fourth quarter results. GAAP EPS in the period came in at -$0.66, beating estimates by $0.07. Revenue in the quarter jumped about 44% year over year to $1.43 billion, missing estimates by $30 million.

Unlike Microsoft Corp (NASDAQ:MSFT), Apple Inc (NASDAQ:AAPL) and Amazon.com Inc (NASDAQ:AMZN), Oscar is a small company that is seeing a rapid share price growth this year.

Longleaf Partners Small-Cap Fund made the following comment about Oscar Health, Inc. (NYSE:OSCR) in its Q3 2023 investor letter:

“Oscar Health, Inc. (NYSE:OSCR) – Health insurance and software platform Oscar Health was the top detractor in the quarter but remains the top performer for the year. Oscar declined in the quarter as venture capital investors that funded the business’ early days reduced their investment. However, nothing fundamentally changed or negatively impacted the value of the business, and Oscar reiterated guidance. CEO Mark Bertolini is focused on closing the significant price-to-value gap. We had trimmed our position in Oscar on the back of strong performance in the first half but added again in the quarter as price declined.”

Click to continue reading and see the 5 Best Booming Stocks to Buy Right Now.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up